TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03186404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 40mg OD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo
Study: NCT03160404

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem
Description: The ZOLPIDEM group will be treated with zolpidem 10mg/night

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The EXERCISE group will participate in an aerobic exercise program, performed in intensity relative to 50% of reserve heart rate, on a treadmill.
Study: NCT00804193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclopirox Olamine Topical Suspension
Description: topical suspension

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclopirox Topical Suspension 0.77%-Reference Product
Description: topical suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ciclopirox Olamine Topical Suspension-Placebo
Description: topical suspension
Study: NCT04182659

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: A non-invasive treatment that emits magnetic pulses to stimulate the brain.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation
Description: Sham rTMS will consist of the same parameters as active, however, the subject will not receive the actual magnetic stimulation due to the use of a double sided Active/Sham coil used specifically for research studies.
Study: NCT01647594

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: YWI
Description: The YWI consists of print and web-based materials. Content for this group will include detailed information about issues facing young women with breast cancer, risks, discussion points and and resources. The following domains will be addressed: health/medical issues (i.e., side effects, breast cancer recurrence, long-term risks, genetic issues), psychosocial issues (coping, relationship and family concerns), beauty/body image, sexual functioning, fertility concerns, and work/school issues.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: The PAI serves as the control group. This intervention consists of print and web-based materials, the content of which includes detailed information about the benefits of exercise in breast cancer survivors and discussion points, available options and resources to enhance physical activity after diagnosis.
Study: NCT02557971

Intervention type: DRUG
Intervention: onabotulinumtoxinA
Description: OnabotulinumtoxinA (BOTOX®) as prescribed in clinical practice.
Study: NCT01596075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Cannabidiol will be dissolved in oil to a predefined concentration.Patients developing grade I/II acute GVHD will be treated by IV or oral methylprednisolone 1-2 mg/kg/day and oral cannabidiol at a starting dose of 10 mg twice daily. Doses of cannabidiol can be escalated every day according to clinical response to a maximal dose of 600 mg/day,if no significant drug related side effects present (CTCAE3 grade\>2). Cannabidiol will be given up to 90 days.
Study: NCT01167036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FascialEdge instrument
Description: Stroking massage to patient tolerance over the muscle
Study: NCT03863574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar Magnesium 2mg
Description: Patients randomly assigned to this group will receive Saroglitazar Magnesium 2 mg tablet orally once daily for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar Magnesium 4mg
Description: Patients randomly assigned to this group will receive Saroglitazar Magnesium 4 mg tablet orally once daily for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Patients randomly assigned to this group will receive Placebo tablet orally once daily for 24 weeks.
Study: NCT03884257

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passeo-18 Lux treatment group
Description: Percutaneous endovascular angioplasty with the Passeo-18 lux
Study: NCT01167036

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo electric point stimulation
Description: Detuned electric point stimulation over the involved muscle
Study: NCT04511650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Razuprotafib Subcutaneous Solution
Description: Up to 3 daily dose levels of Razuprotafib Subcutaneous Solution will be evaluated. Doses will be administered subcutaneously three times daily (Q8H) for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Razuprotafib Subcutaneous Solution
Description: Up to 3 daily dose levels of Razuprotafib Subcutaneous Solution will be evaluated. Doses will be administered subcutaneously three times daily (Q8H) for 7 days.
Study: NCT03884257

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IN.PACT Admiral treatment group
Description: Percutaneous endovascular angioplasty with the IN.PACT Admiral
Study: NCT04171895

Intervention type: OTHER
Intervention: Questionnaires
Description: Will be filled out before and after the training so investigators can evaluate the skills learned and how they can be used them in advanced care planning. Questionnaires will be available in both paper form and electronic via REDCap.

Intervention type: OTHER
Intervention: Questionnaires
Description: Will be filled out before and after the training so investigators can evaluate the skills learned and how they can be used them in advanced care planning. Questionnaires will be available in both paper form and electronic via REDCap.

Intervention type: OTHER
Intervention: Communication training Part 1 (no longer recruiting)
Description: 1.5 hour Communication Training will be delivered through videoconferencing using the WebEx or Zoom platforms. The Training consists of a 30-minute lecture watched independently, and two modules (ACP Discussions with your Loved One and ACP Discussions with the Medical Team) completed as part of a virtual meeting. The lecture will be pre-recorded by Drs. Applebaum and Parker and will be sent via REDCap to ICs prior to the training to watch idependently. REDCap will log when ICs watch the lecture so that study staff know the participant has completed this aspect of the training. For the second part of the training ICs will participate in a virtual meeting for approximately 90 minutes of experiential role-play exercises where ICs will practice skills in simulated encounters with actors trained to play patients and HCPs.

Intervention type: OTHER
Intervention: Enhanced usual care
Description: Participant will complete a survey on distress and receive feedback about distress and given a resource packet with support information and targeted referrals based on needs. The participant will also receive a physical or electronic copy of a book entitled Cancer Caregiving A to Z published by the American Cancer Society. At the conclusion of their participation in the study, EUC participants will be given access to the pre-training video and Advanced Care Planning forms sent to Communication Training participants.

Intervention type: OTHER
Intervention: Communication training Part II
Description: Part II The communication training developed in Part 1 will have two modules (ACP Discussions with your Loved One and ACP Discussions with the Medical Team) and consist of a 20-30 minute lecture and 90 minutes of experiential role-play exercises where ICs will practice skills in simulated encounters with actors trained to play patients and HCPs. Realistic scenarios were created and tailored according to ICs' reported concerns. After training, ICs will be coached through setting a SMART goal related to conducting ACP conversations, which emphasize Specific, Measurable, Attainable, Relevant and Time-bound steps that motivate and direct behavior change. Two weeks post training, a booster phone call will be made to ICs to check progress toward their SMART goal, address barriers with problem-solving and review skills as indicated.
Study: NCT04832698

Intervention type: OTHER
Intervention: Survey Administration
Description: Complete survey
Study: NCT03985527

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transvenous nerve stimulation
Description: Acute transvenous nerve stimulation during a commercial implant of remedē® System or commercial transvenous cardiac device (de novo pacemaker or implantable cardiac defibrillator).
Study: NCT04511650

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Subcutaneous Solution
Description: Matched vehicle-controlled placebo solution will be administered subcutaneously three times daily (Q8H) for 7 days
Study: NCT01571037

Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled, nebulized, Milrinone
Description: 1 mg/ml milrinone (dissolved in dextrose) and diluted in 0.9% normal saline in a 1:1 ratio to final drug concentration of 0.5mg/ml will be delivered via an IV pump at a fixed dose of 12 ml/hour which will run into a vibrating mesh nebulizer reservoir, connected to the mechanical ventilator circuit. Inhaled milrinone will begin at time of resumption of mechanical ventilation when initiating wean from cardiopulmonary bypass after LVAD implantation in the operating room, and run continuously for a total maximum duration of 24 hours OR until the patient is extubated whichever occurs first. Plasma milrinone levels will be assessed to determine if systemic milrinone absorption occurs after prolonged milrinone inhalation.
Study: NCT01083862

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Intervention - Text plus DVD/VHS
Description: In conjunction with a scheduled clinical visit, consenting patients spent roughly 40 minutes viewing a video program developed by the Foundation for Informed Decision Making (FIMDM), describing life-style and behavior modification for patients Living with Coronary Artery Disease. They also were given a booklet on the same subject material written at a 5th grade level.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention - Text Only
Description: In conjunction with a scheduled clinical visit, consenting patients spent roughly 40 minutes reading a booklet developed by the Foundation for Informed Decision Making (FIMDM), describing life-style and behavior modification for patients Living with Coronary Artery Disease. Subject material was written at a 5th grade level.
Study: NCT00442351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asmanex twisthaler
Description: Asmanex Twisthaler 220 mcg provided once daily in the evening for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Asmanex twisthaler
Description: Placebo for Asmanex Twisthaler 220 mcg, once daily in the evening for 12 weeks
Study: NCT00491257

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine (split virion) NH 2007-2008 formulation
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine (split virion) NH 2007-2008 formulation
Description: 0.5 mL, Intramuscular
Study: NCT00894933

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONTINUUM™
Description: Performance of CONTINUUM™ in facilitating the vesico-urethral anastomosis following radical prostatectomy.
Study: NCT01859026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: Treatment as outlined in study arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: Treatment as outlined in study arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: Treatment as outlined in study arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Treatment as outlined in study arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Treatment as outlined in study arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Treatment as outlined in study arms.
Study: NCT04977596

Intervention type: OTHER
Intervention: No intervention
Description: Retrospective study without intervention

Intervention type: OTHER
Intervention: No intervention
Description: Retrospective study without intervention
Study: NCT00230594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desmopressin
Description: desmopressin 120 mcg melt tablet; 120 mcg, 240 mcg or 360 mcg administered once daily before bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo melt tablet; 1 to 3 placebo melt tablets administered once daily before bedtime
Study: NCT04204226

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Worker
Description: The social worker will discuss the clinician's recommendations for needed services and how to access the services. The family will be provided the social worker's contact information and be encouraged to reach out with more questions or if more information is needed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autism Behavioral Health Navigation (ABHN)
Description: The goal of the ABHN intervention is to ensure access to recommended community behavioral health services, decrease parent stress levels, and/or improve child sleep and activity levels in order to reduce disruptive behaviors. Navigators will check-in at least weekly by telephone, email, or text message (as per family preference) during the first 4 weeks of the intervention and at least every 2 weeks for the remainder of the intervention or until ABHN and family agree that all goals and action steps in the Family Care Plan are completed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social work + ABHN
Description: After 3 months, children whose ABC Irritability Subscale scores improve by less than 5 points who received the social work intervention can be randomized to ABHN

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social work + ABHN + CAP
Description: After 3 months, children whose ABC Irritability Subscale scores improve by less than 5 points who received the social work intervention can be randomized to ABHN+Complex Autism Program (CAP)
Study: NCT03818295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-praliciguat
Description: 10 mg praliciguat containing approximately 500 μCi of \[14C\]-praliciguat
Study: NCT00695383

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bedside cycle exercise therapy
Description: A 20-minute cycling exercise session is performed 5 days a week using a bedside cycle ergometer. Patients can cycle passively and actively against increasing resistance. Besides this, patients receive the standard physiotherapy program as in arm 2

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard physiotherapy program
Description: The standard physiotherapy program consists of daily chest physiotherapy and a mobilization session on 5 days per week.
Study: NCT00587431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRh (Leuprolide)
Description: Leuprolide LUPRON

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRh (Leuprolide)
Description: Leuprolide LUPRON

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Gel
Description: Starting during week 3 (day 19) of cycle 1, 7.5G applied topically daily for 3 days (applied at approximately 9p)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Gel
Description: Starting during week 3 (day 19) of cycle 1, 7.5G applied topically daily for 3 days (applied at approximately 9p)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 70 mg/m2 given on day o1 of each 3 week cycle
Study: NCT03424655

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Twisted File Adaptive
Description: Twisted file adaptive SM1 (size 20, .04 taper) and SM2 (size 25, .06 taper) were used serially with a single controlled motion according to the manufacturer's instructions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balance Force
Description: Flex-R files sizes 15-45 taper .02 were used according to the technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WaveOne
Description: WaveOne instrument was used to prepare narrow, straight and curved canals, and file (40.08) was used for large canals.~Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reciproc technique
Description: Reciproc files were used in wide canals. Three in-and-out motions were used with lengths not beyond 3 mm in the three thirds of the canal until reaching the estimated WL.
Study: NCT00804024

Intervention type: DEVICE
Intervention: ClearWay™ RX Local Therapeutic Infusion Catheter
Description: The ClearWay™ RX Local Therapeutic Infusion Catheter is a micro-porous PTFE balloon catheter designed for the localized infusion of various diagnostic and therapeutic agents into the coronary and peripheral vasculature.
Study: NCT01034852

Intervention type: PROCEDURE
Intervention: Totally Thoracoscopic Maze
Description: Epicardial pulmonary vein isolation with additional lesions as determined to be necessary by physician
Study: NCT00769314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir Lauriad
Description: 50 mg muco-adhesive buccal tablets, single application on the gum

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 mg muco-adhesive buccal tablets, single application on the gum
Study: NCT04372719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H3N2
Study: NCT04702035

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Characterization of walking pattern characteristics in an ambulatory setting using wearable IMUs (ZurichMOVE sensors)
Description: All participants receive a set of 5 wearable IMUs for a period of 3 days. The IMUs are fixed at both wrists, ankles and one over the sternum. A 10-meter walking test, 180 degree turnaround test and normal walking at home are performed. Afterwards, the IMUs are removed for data extraction and evaluation. The patient group is examined a second time after CSF diversion surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Characterization of walking pattern characteristics in an ambulatory setting using wearable IMUs (ZurichMOVE sensors)
Description: All participants receive a set of 5 wearable IMUs for a period of 3 days. The IMUs are fixed at both wrists, ankles and one over the sternum. A 10-meter walking test, 180 degree turnaround test and normal walking at home are performed. Afterwards, the IMUs are removed for data extraction and evaluation. The patient group is examined a second time after CSF diversion surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Characterization of walking pattern characteristics in an ambulatory setting using wearable IMUs (ZurichMOVE sensors)
Description: All participants receive a set of 5 wearable IMUs for a period of 3 days. The IMUs are fixed at both wrists, ankles and one over the sternum. A 10-meter walking test, 180 degree turnaround test and normal walking at home are performed. Afterwards, the IMUs are removed for data extraction and evaluation. The patient group is examined a second time after CSF diversion surgery.
Study: NCT01102452

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Commercially Available Wet Noodle
Description: Commercially Available Wet Noodle will be served as a diet equivalent to daily energy needs as judged by indirect calorimetry and of same macronutrient composition.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PPB-R-203-02 Noodle
Description: PPB-R-203-02 Noodle is manufacture by Pharma Power Biotec Co., Ltd. The composition of PPB-R-203-02 Noodle is resistant starch (RS). By definition, resistant starch (RS) is any starch that is not digested in the small intestine but passes to the large intestine (or the colon). Therefore, resistant starch can be regarded as a component of dietary fiber. PPB-R-203-02 Noodle will be served as a diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
Study: NCT03474328

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AlcoChange
Description: Smartphone app and breathalyser
Study: NCT02674386

Intervention type: DRUG
Group type: OTHER
Intervention: Investigational Medical Product (IMP) administered in parent study
Description: IMP as administered in parent study. IMP would have been either placebo, tanezumab, celecoxib, naproxen or diclofenac administered in parent study.
Study: NCT01634412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL TNX-102 2.4 mg at pH 3.5
Description: 1 dose of 2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 3.5, administered as 1 mL held under the tongue for 90 seconds without swallowing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL TNX-102 2.4 mg at pH 7.1
Description: 1 dose of 2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 7.1, administered as 1 mL held under the tongue for 90 seconds without swallowing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclobenzaprine Tablet
Description: 1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclobenzaprine IV
Description: 1 dose of 2.4 mg cyclobenzaprine USP in PBS (0.6 mg/mL) at pH 7.4, administered intravenously as a 4 mL bolus injection over 30 seconds
Study: NCT00754871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dienogest (81150037)
Description: daily oral intake of 0.5 mg dienogest over two cycles or a max. of 72 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dienogest (81150231)
Description: daily oral intake of 1.0 mg dienogest over two cycles or a max. of 72 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dienogest (SH T00660A)
Description: daily oral intake of 2.0 mg dienogest over two cycles or a max. of 72 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dienogest (81150746)
Description: daily oral intake of 3.0 mg dienogest over two cycles or a max. of 72 days
Study: NCT03224520

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recommender CTHC
Description: Enhanced Messaging

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recommender CTHC
Description: Enhanced Messaging

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard CTHC
Description: Standard Messaging

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard CTHC
Description: Standard Messaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer Recruitment
Description: Tools to facilitate smokers' recruiting their peers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer Recruitment
Description: Tools to facilitate smokers' recruiting their peers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Online Recruitment
Description: Search Engine and Social Media Advertisements

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Online Recruitment
Description: Search Engine and Social Media Advertisements